Plus Therapeutics, Inc. PSTV
We take great care to ensure that the data presented and summarized in this overview for PLUS THERAPEUTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in PSTV
Top Purchases
Top Sells
About PSTV
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Insider Transactions at PSTV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Sep 13
2024
|
Richard J Hawkins |
BUY
Open market or private purchase
|
Direct |
4,000
+20.85%
|
$4,000
$1.5 P/Share
|
|
Sep 12
2024
|
Richard J Hawkins |
BUY
Open market or private purchase
|
Direct |
6,285
+35.97%
|
$6,285
$1.35 P/Share
|
|
Sep 11
2024
|
Howard Clowes |
BUY
Open market or private purchase
|
Direct |
5,000
+15.87%
|
$5,000
$1.34 P/Share
|
|
Sep 11
2024
|
Greg Petersen |
BUY
Open market or private purchase
|
Direct |
12,500
+20.35%
|
$12,500
$1.35 P/Share
|
|
Sep 10
2024
|
Marc H Hedrick Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
8,000
+28.14%
|
$8,000
$1.23 P/Share
|
|
Sep 10
2024
|
Andrew John Hugh Mac Intyre Sims Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
4,098
+29.45%
|
$4,098
$1.27 P/Share
|
|
May 08
2024
|
Robert P Lenk |
BUY
Open market or private purchase
|
Direct |
4,167
+12.44%
|
$8,334
$2.04 P/Share
|
|
May 08
2024
|
Richard J Hawkins |
BUY
Open market or private purchase
|
Direct |
4,902
+49.99%
|
$9,804
$2.04 P/Share
|
|
May 08
2024
|
Howard Clowes |
BUY
Open market or private purchase
|
Direct |
9,804
+31.32%
|
$19,608
$2.04 P/Share
|
|
May 08
2024
|
Greg Petersen |
BUY
Open market or private purchase
|
Direct |
12,255
+25.18%
|
$24,510
$2.04 P/Share
|
|
May 08
2024
|
Marc H Hedrick Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
12,255
+49.66%
|
$24,510
$2.04 P/Share
|
|
May 08
2024
|
Andrew John Hugh Mac Intyre Sims Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
4,902
+46.16%
|
$9,804
$2.04 P/Share
|
|
Nov 20
2023
|
Marc H Hedrick Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,068
-92.4%
|
$2,068
$1.96 P/Share
|
|
Nov 16
2023
|
Robert P Lenk |
BUY
Open market or private purchase
|
Direct |
1,000
+3.82%
|
$1,000
$1.95 P/Share
|
|
Nov 15
2023
|
Robert P Lenk |
BUY
Open market or private purchase
|
Direct |
1,000
+3.97%
|
$1,000
$1.77 P/Share
|
|
Nov 13
2023
|
Robert P Lenk |
BUY
Open market or private purchase
|
Direct |
4,000
+14.73%
|
$4,000
$1.43 P/Share
|
|
Nov 10
2023
|
Robert P Lenk |
BUY
Open market or private purchase
|
Direct |
2,000
+9.45%
|
$2,000
$1.45 P/Share
|
|
Nov 09
2023
|
Robert P Lenk |
BUY
Open market or private purchase
|
Direct |
4,199
+19.66%
|
$4,199
$1.59 P/Share
|
|
Nov 08
2023
|
Robert P Lenk |
BUY
Open market or private purchase
|
Direct |
5,000
+27.84%
|
$5,000
$1.65 P/Share
|
|
Nov 07
2023
|
Robert P Lenk |
BUY
Open market or private purchase
|
Direct |
6,000
+42.98%
|
$6,000
$1.64 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 88.2K shares |
|---|